# Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors

> **NCT06872489** · — · AVAILABLE · sponsor: **Second Life Therapeutics**

## Conditions studied

- Neuroblastoma in Children
- Neuroblastoma, Recurrent, Refractory
- Advanced Cancer
- Advanced Malignant Neoplasm
- Prostate Cancer Patients With Bone Metastasis
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Lung Cancer - Non Small Cell
- Gastrointestinal Cancers
- Head and Neck Cancer
- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** SL-28.

## Key facts

- **NCT ID:** NCT06872489
- **Lead sponsor:** Second Life Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06872489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06872489, "Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06872489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*